LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Clinical trials for LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat breast cancer: phase 3 trial launches
Disease control Not yet recruitingThis phase 3 trial compares a new drug called 9MW2821 to standard chemotherapy in 356 people with advanced triple-negative breast cancer who have already received certain prior treatments. The main goal is to see if the new drug helps people live longer. Participants will receive…
Matched conditions: LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New combo aims to shield bone marrow in tough breast cancer
Disease control Not yet recruitingThis phase 2 trial tests whether adding trilaciclib to the chemotherapy drug eribulin can protect bone marrow in people with advanced triple-negative breast cancer who have already tried at least two chemotherapies. The study will enroll 29 participants and measure how often seve…
Matched conditions: LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC